OOIR: Observatory of International Research

Papers

(The H4-Index of Haematologica is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Bence Jones Island in Shepherd Bay, Nunavut: a little known tribute to the legendary physician and chemist’s “thé de voyage”	219
Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma	137
Genome-wide assessment of genetic risk loci for childhood acute lymphoblastic leukemia in Japanese patients	90
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation	87
The first human acute myeloid leukemia genome ever fully sequenced	80
Impact of soluble thrombomodulin and activated protein C on dynamic hemostatic function in trauma: a focus on thrombin generation and clot lysis	70
Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice	70
BCL2 inhibition in adult acute lymphoblastic leukemia: ready for primetime?	70
Genetic risk classification in acute myeloid leukemia patients treated with hematopoietic cell transplantation and post-transplant cyclophosphamide	62
Asparaginase-associated hyperammonemia	61
The polymerase chain reaction, so simple, so clever: the discovery that made minimal residual disease come true	60
Acute myeloid leukemia at first relapse: approaching the precipice	57
Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia – the CONS	55
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection	54
Old methods, lasting impact in relapsed/refractory primary mediastinal B-cell lymphoma	54
Asparaginase dosing for acute lymphoblastic leukemia: more questions than answers	53
PHF6 interacts with the LMO2 complex in T-cell acute lymphoblastic leukemia	53
Comprehensive characterization of human bone marrow microenvironment shows age-related changes	52
Relapsed classic Hodgkin lymphoma; should all patients receive an autologous stem cell transplant? – the PRO	51
Genetic testing guides therapy in children with refractory cytopenias	51
P67 \| TALQUETAMAB INDUCES DEEP RESPONSES IN HEAVILY PRE-TREATED PATIENTS WITH SYSTEMIC LIGHT-CHAIN AMYLOIDOSIS	50
P59 \| BISPECIFIC ANTIBODIES IN FRAIL AND ELDERLY MULTIPLE MYELOMA PATIENTS WITH ECOG >1: REAL-WORLD IMPACT OF PERFORMANCE STATUS AND DOSE MODIFICATIONS ON OUTCOMES	44
“ASXL1”-erating inflammation and bone marrow fibrosis in myeloproliferative neoplasms	43
Bipartite <i>NUP98</i>::<i>RARA</i>-E412* fusion with a <i>cis</i>-aligned ligand binding domain truncation mutation in atypical acute promyelocytic leukemia	43
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R	42

The patient voice: measuring what matters in lower-risk myelodysplastic syndromes treated with imetelstat	41
The dilemma after chimeric antigen receptor T-cell therapy – to transplant or not?	39
Scott syndrome with novel compound heterozygous pathogenic variants in <i>ANO6</i> and reduced thrombin generation	36
Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma	36
CO42 \| Dynamic changes after allogeneic stem cell transplantation of extracellular vesicles originated from platelets, endothelial cells and leukocytes after: correlation with acute graft-versus-host	35
CO05 \| Identification of <i>wnk1</i> as a druggable target in <i>TAL1</i>-related T-cell acute lymphoblastic leukemia	34
Clonal plasma cell features in light-chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response	34
Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial	33
Venetoclax combined with escalating doses of homoharringtonine, low-dose cytarabine, and granulocyte colony-stimulating factor demonstrates feasibility and tolerability for remission induction in pedi	33